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Abstract
Objective: Microglia play a pivotal role in the initiation and progression of
Alzheimer’s disease (AD). We here tested the therapeutic hypothesis that the
Ca2+-activated potassium channel KCa3.1 constitutes a potential target for
treating AD by reducing neuroinflammation. Methods: To determine if KCa3.1
is relevant to AD, we tested if treating cultured microglia or hippocampal slices
with Ab oligomer (AbO) activated KCa3.1 in microglia, and if microglial
KCa3.1 was upregulated in 5xFAD mice and in human AD brains. The expres-
sion/activity of KCa3.1 was examined by qPCR, Western blotting, immunohis-
tochemistry, and whole-cell patch-clamp. To investigate the role of KCa3.1 in
AD pathology, we resynthesized senicapoc, a clinically tested KCa3.1 blocker,
and determined its pharmacokinetic properties and its effect on microglial acti-
vation, Ab deposition and hippocampal long-term potentiation (hLTP) in
5xFAD mice. Results: We found markedly enhanced microglial KCa3.1 expres-
sion/activity in brains of both 5xFAD mice and AD patients. In hippocampal
slices, microglial KCa3.1 expression/activity was increased by AbO treatment,
and its inhibition diminished the proinflammatory and hLTP-impairing activi-
ties of AbO. Senicapoc exhibited excellent brain penetrance and oral availabil-
ity, and in 5xFAD mice, reduced neuroinflammation, decreased cerebral
amyloid load, and enhanced hippocampal neuronal plasticity. Interpretation:
Our results prompt us to propose repurposing senicapoc for AD clinical trials,
as senicapoc has excellent pharmacological properties and was safe and well-tol-
erated in a prior phase-3 clinical trial for sickle cell anemia. Such repurposing
has the potential to expedite the urgently needed new drug discovery for AD.
Introduction
Emerging evidence strongly implicates aberrant microglial
activation in Alzheimer’s disease (AD).1–3 The functional
and pathological diversity of microglia is orchestrated by
a complex ensemble of ion channels, receptors, and trans-
porters that regulate intracellular signaling and gene
expression. Activities of these surface molecules can be
modulated selectively in order to modify microglial acti-
vation. One possible target is KCa3.1, an intermediate-
conductance Ca2+-activated K+ channel expressed in
immune cells such as T-lymphocytes, macrophages and
microglia.4,5 In these cells, KCa3.1 regulates cellular acti-
vation, migration and proliferation via K+ efflux, which
helps maintain a negative membrane potential to drive
Ca2+ influx required for various activities.6,7 We and
others previously demonstrated that rat8 and mouse9
microglia express KCa3.1, but do not display other KCa
currents carried by KCa1.1 and KCa2 channels.9 We fur-
ther demonstrated that microglial activation and neuro-
toxicity induced by Ab oligomer (AbO), the most toxic
amyloid in AD brains, can be blocked by the specific
KCa3.1 blocker TRAM-34 in vitro, suggesting that KCa3.1
could be a therapeutic target for AD.9,10
In the current study, we used animal models and
human postmortem brain samples to show that KCa3.1 is
a biologically relevant and microglial target for AD. We
further showed that an orally available KCa3.1 inhibitor
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called senicapoc was able to mitigate AD-like deficits in
5xFAD mice. We further found that senicapoc exhibited
good brain penetration (Cbrain/Cplasma~5). Senicapoc was
previously advanced to a Phase-3 clinical trial for sickle cell
anemia and was found to be safe and well-tolerated.11–13
Our results provide a strong rationale to repurpose seni-
capoc for the treatment of AD and/or mild cognitive
impairment.
Methods and Materials
Study approval
All protocols involving mouse models were approved by
the Institutional Animal Care and Use Committee.
Human brain samples were provided by the University of
California Davis Alzheimer’s Disease Center, approved by
the Institutional Review Board.
Mouse model
Tg6799 5xFAD mice on the C57Bl/6 background were
obtained from Dr. Robert Vassar.14 This line co-expresses
human APP695 with the Swedish (K670N, M671L), Flor-
ida (I716V), and London (V717I) mutations and human
PS1 harboring M146L and L286V mutations. Mice were
randomly assigned to treatment groups and phenotyping
parameters were evaluated in a blinded manner. Roughly
equal numbers of male and females mice were used.
Chemicals and diets
TRAM-34 and 4-phenyl-4H-pyran (methyl-5-acetyl-4-(4-
chloro-3-(trifluoromethyl)phenyl)-2,6-dimethyl-4H-
pyran-3-carboxylate) were synthesized as described.15 Sen-
icapoc was synthesized as shown in Figure 6A and its
purity and identity authenticated (Data S1). For intraperi-
toneal administration of TRAM-34, animals received
either the vehicle Miglyol-812 (caprylic/capric triglyceride,
Spectrum Chemicals) or TRAM-34 (40 mg/kg) dissolved
in Miglyol-812. For diet administration of senicapoc,
animal received either a senicapoc-medicated diet
(2400 ppm, Harlan TD.140594) or a control diet (Harlan
TD.140368).
Tissue culture and acute isolation of
microglia
Primary microglia were prepared from mixed glia cultures
as described.9 Hippocampal slice cultures (400 lm thick)
were prepared from 7-day-old C57BL/6 mice as
described9 and cultured for 10 days before use. To study
microglia in adult mouse brains without culturing,
microglia were acutely isolated as described using anti-
CD11b magnetic beads (Miltenyi Biotec).16
Production of AbO
AbO was prepared and characterized as described.16 To
ensure consistency, a random sample from each batch
was evaluated for neurotoxic activity and ability to rapidly
induce exocytosis of MTT formazan, as described.17,18
Whole-cell patch-clamp
Whole-cell patch-clamp studies on cultured primary micro-
glia and isolated adult microglia were conducted as
described.9,16,19 KCa3.1 conductances were calculated from
the slope of the TRAM-34-sensitive KCa current between 80
and 75 mV, where, under our recording conditions with
an aspartate-based internal solution, KCa3.1 currents are pri-
marily carried by KCa3.1 and not “contaminated” with Kv1.3
(which activates at voltages more positive than 40 mV),
inward rectifier K+ currents (which are appreciable at
voltages more negative than 80 mV), or chloride currents.
Cell/tissue homogenate preparation,
Western blot analysis, and Ab ELISA
To obtain cell lysates, cells were washed with ice-cold PBS
and incubated and harvested with a lysis buffer
(150 mmol/L NaCl, 10 mmol/L NaH2PO4, 1 mmol/L
EDTA, 1% TritonX100, 0.5% SDS) with protease inhibitor
cocktail and phosphatase inhibitor (Sigma). Mouse and
human brain were homogenized in RIPA buffer (Thermo-
Fisher) with protease inhibitor cocktail and phosphatase
inhibitor (Sigma) and used for Western blotting as
described.9 The following primary antibodies (dilutions)
were used: anti-KCa3.1 P4997 (1:1000, Sigma), anti-phos-
pho P38MAPK and anti-P38MAPK (1:1000, Cell Signal-
ing), anti-b actin (1:3000, Sigma), and anti-GAPDH
(1:2000, Cell Signaling). Secondary antibodies were HRP-
conjugated anti-rabbit or anti-mouse antibody (1:1000, GE
Healthcare). Brain tissue samples from 5xFAD treated with
senicapoc or control diet were fractionated into TBS-solu-
ble and TBS-insoluble, SDS-soluble fractions, which were
used for Ab42 quantification by a Human Ab42 ELISA kit
(Wako) as described.16 Alternatively, Ab in each fraction
was separated in 16.5% Tris/Tricine SDS gel electrophore-
sis (Bio-Rad), transferred to PVDF membrane, and
detected by anti-Ab (6E10, 1:1000, BioLegend).
Quantitative PCR
Total RNA from primary microglia, acutely isolated
microglia, and tissue samples were extracted using RNeasy
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Plus Mini Kit (Qiagen) or RNeasy Plus Universal Mini
Kit (Qiagen). RNA samples from acutely isolated micro-
glia were further reverse-transcribed and pre-amplified as
we previously described.20 The result was normalized to
b–actin. The primer sequences used are listed in Table 1.
Relative cDNA levels for the target genes were analyzed
by the 2-ΔΔCt method using Actb as the internal control
for normalization.
Immunofluorescence staining
Immunofluorescence staining and quantification was per-
formed as described.16 Briefly, microglia cells cultured on
cover slip, hippocampal slices and frozen mouse or
human brain sections (20 lm) were fixed and stained
with anti-Ab1-42 (1:200; Millipore), anti-CD68 (1:200;
Serotec), anti-CD11b (1:200; AbD Serotec), or anti-Iba-1
(1:200, Wako Chemical or Millipore), overnight at 4°C,
followed by respective Alexa Fluor-conjugated secondary
antibodies (1:700; Invitrogen). For detection of amyloid
plaques, 400 nmol/L FSB (Sigma) was used. To detect
mouse KCa3.1, the following antibodies were used:
APC064 (1:3000, Alomone Labs), P4997 (1:3000, Sigma),
AV35098 (1:3000, Sigma), and SC-365265 (1:3000, Santa
Cruz). Noticeably, SC-365265 was used in prior studies to
support astrocytic expression of KCa3.1.21,22 However,
SC-365265 highlighted multiple cellular contours
throughout the brain in KCa3.1/ mice, even at a 1:3000
dilution (data not presented), therefore was considered
nonspecific and not further used. For human brains, an
additional anti-human KCa3.1 polyclonal antibody
(1:300, ThermoFisher PA5:41015) was used. Before FSB
(1 lmol/L) staining, sections were incubated with 0.1%
Sudan black B (Sigma) to block autofluorescence.
Immunostained slides were imaged under a Nikon Eclipse
E600 microscope and photographed by a digital camera
(SPOT RTke, SPOT Diagnostics). Photomicrographs were
randomly taken in a blind fashion and then analyzed by
ImageJ as described.16 For co-localization analysis to
determine % of microglia expressing KCa3.1, three pho-
tomicrographs from each mouse were analyzed by a Fiji
Coloc2 plugin (co-localization analysis program, https://
imagej.net/Coloc_2). The photography and analysis of
immunoreactivity were conducted in an investigator-
blinded manner.
Induction of hippocampal long-term
potentiation by high frequency stimulation
See Data S1.
Pharmacokinetic study of senicapoc
Total senicapoc plasma and brain concentrations were
determined by LC-MS analysis using a Waters Acquity
UPLC (Waters) interfaced to a TSQ Quantum Access
Max mass spectrometer (ThermoFisher Scientific) (Data
S1). Basic pharmacokinetic properties (brain/plasma
ratios; brain/plasma profiles and oral availability) are
shown in Figure 6.
Statistics
All results were expressed as the mean  S.E, or
mean  S.D. in pharmacokinetics data. Normality of the
data distribution was determined using the Shapiro-Wilk
test. For group comparisons in means, paired or unpaired
Student’s t-test or one or two-way ANOVA, as appropri-
ate, were conducted using the SigmaStat 3.1 (Systat Inc.).
When the overall ANOVA was significant, Bonferroni’s
Table 1. qPCR primer list.
Gene Forward Primer (50–>30} Reverse Primer (30–>50)
IL-1b (il1b) CCCCAAGCAATACCCAAAGA TACCAGTTGGGGAACTCTG
TNF-a (tnfa) GACGTGGAACTGGCAGAAGAG TGCCACAAGCAGGAATGAGA
IL-6 (il6) GTTCTCTGGGAAATCGTGGA TTCTGCAAGTGCATCATCGT
Arg1 (arg1) CCAACTCTTGGGAAGACAGC TATGGTTACCCTCCCGTTGA
iNOS (inos2) CGGATAGGCAGAGATTGGAG GTGGGGTTGTTGCTGAACTT
CD206 (cd206) TCATCCCTGTCTCTGTTCAGC ATGGCACTTAGAGCGTCCAC
Ym2 (chil3) AGGAAGCCCTCCTAAGGACA TGAGTAGCAGCCTTGGAATG
IGF-1 (igf1) CACAATGCCTGTCTGAGGTG TGAGTAGCAGCCTTGGAATG
CaMK2-a (camk2a) CAATATCGTCCGACTCCATG CATCTGGTGACAGTGTAGC
CD11b (cd11b) AAGGATTCAGCAAGCCAGAA GGAGGGATGAGAGTCCACAT
Nav1.8 (Scn10a) QuantiTect Primer Assay (QIAGEN, Mm_Scn10a_1_SG)
GFAP (Gfap) PrimerPCR
TM SYBR Green Assay (Bio-Rad, qMmuCID0020163)
Kca3.1 (Kcnn4) PrimePCR
TM SYBR Green Assay (Bio-Rad, qMmuCID0016996)
b-actin (ACTB) Mouse ACTB (Applied Biosystems, Mm00607939_s1)
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multiple comparison procedure was carried out to main-
tain the family wise error rate at 0.05. The significance
level for the two-sided analyses was set at P < 0.05. If the
assumption of normality was violated, a natural log trans-
form of the outcome was used and reassessed for normal-
ity. If normality was still violated, a nonparametric
Wilcoxon rank sum test was used instead of the t-test.
Results
KCa3.1 is upregulation by AbO in microglia
Previously we and others have verified the biophysical
and pharmacological signatures of KCa3.1 in primary cul-
tured or acutely isolated adult mouse, rat, and human
microglia, and shown that KCa3.1 plays an important role
in regulating microglial activation.9,23,24 Expression analy-
sis further showed that only microglia expressed signifi-
cant amounts of KCa3.1 among neural cells (Fig. 1A). In
organotypic hippocampal slice cultures, a more physiolog-
ical model, AbO substantially increased the number of
strongly CD11b-immunoreactive microglia, a large major-
ity of which were also KCa3.1-positive (Fig. 1B). qPCR
(Fig. 1C) and Western blotting (Fig. 1D) further showed
parallel increases in the transcript and protein levels of
KCa3.1. We did not observe significant co-localization of
the astrocytic marker GFAP with KCa3.1, suggesting that
AbO did not upregulate KCa3.1 in astrocytes (Fig. 1B).
Microglial KCa3.1 expression/activity is
enhanced in 5xFAD mouse and human AD
brains
To investigate the in vivo role of microglial KCa3.1, we
used 5xFAD mice, which harbor five familial mutations of
APP and PSEN1 genes and show robust Ab production
and Ab-associated neuroinflammation.14 Soluble AbO
made of Ab42 is a major species of Ab aggregates in 5xFAD
mice25 and could stimulate microglial KCa3.1 expression
in vivo. We observed substantial increases in both CD11b
and KCa3.1 immunoreactivities in four and ten months-
old 5xFAD brains (Fig. 2A, D, and Fig. S1) compared to
age-matched Wt littermates. Two antibodies, APC064 and
P4997, were used and both showed that KCa3.1 was local-
ized to CD11b-positive microglial cell bodies or processes
(Fig. 2A). Higher magnification revealed that KCa3.1
appeared distributed differently from CD11b within micro-
glia. For example, KCa3.1 immunostaining was localized to
segments of microglial processes, contiguous (Fig. 2B,
arrowheads) or overlapping with CD11b-positive curvilin-
ear profiles. qPCR (Fig. 2C) and Western blotting
(Fig. 2D) confirmed the increased level of KCa3.1 tran-
script and protein, respectively, in 5xFAD brains. Notably,
KCa3.1 expression was not different between Wt and
5xFAD mice at one month of age, but began to increase in
5xFAD mice at 4 months of age. This appears to concomi-
tant with Ab amyloidosis and microglial activation in
5xFAD mice, which began at 3–4 months of age.
To confirm that KCa3.1 in 5xFAD microglia is func-
tional, we performed whole-cell patch-clamp on microglia
acutely isolated from brains of 10-months-old 5xFAD and
Wt littermates. The purity of isolated microglia, deter-
mined by flow cytometry, was consistently between 94 to
96%.26 Compared to Wt microglia (Fig. 3A), 5xFAD
microglia displayed enhanced expression of a TRAM-34-
sensitive KCa3.1 current when dialyzed with 1 lmol/L of
free Ca2+ (Fig. 3B). The K+ current remaining after appli-
cation of 1 lmol/L of TRAM-34 was carried by a combi-
nation the voltage-gated Kv1.3 current (at potentials above
40 mV) and the inward-rectifier Kir2.1 (at potentials
below 90 mV), two other major K+ currents expressed
in microglia.16,27 Quantification of the TRAM-34-sensitive
current density, which puts the current amplitude in rela-
tion to cell size, shows a significant increase in functional
KCa3.1 expression in 5xFAD microglia (Fig. 3C).
We next compared KCa3.1 expression in the superior
temporal cortex of thirteen pathologically confirmed AD
(“high likelihood of AD” according to the National Insti-
tute on Aging-Alzheimer’s Association guideline28 and
Braak stage 5 and 6 according to the BrainNet Europe
criteria29) and nine age-matched control (cognitively
intact with Braak stage 0–2) individuals (Table 2).
Immunofluorescence stains highlighted strongly KCa3.1-
positive microglia in AD brains that were much less
numerous in control brains (Fig. 4A). KCa3.1 immunore-
activities, assessed by two independent antibodies, were
accentuated in or around FSB-positive amyloid plaques
and showed substantial co-localization with Iba-1, a
microglia marker (Fig. 4B, arrows). Interestingly, KCa3.1
appeared distributed differently from Iba-1 within same
microglia. Substantial co-localization was also found with
CD68, a microglia/macrophage marker, but not with
GFAP, an astrocytic marker (Fig. S2). Western blotting
showed that human brains express a KCa3.1-immunor-
eactive band slightly below the 50 kDa mark, consistent
with that seen in mouse brains and a predicted molecular
mass of 47.7 kDa (Fig. 4C). Quantitation of KCa3.1 band
intensities revealed a substantial increase in AD brains
compared to control brains (Fig. 4D).
KCa3.1 inhibition mitigates AbO-induced
impairment in hippocampal long-term
potentiation
hLTP is considered a cellular correlate of learning and
memory. Ab was shown to inhibit induction of NMDA
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AB C
D
Figure 1. KCa3.1 is expressed in microglia and is upregulated by AbO. (A) qPCR was conducted on RNA extracted from cultured primary mouse
microglia, astrocytes and neurons from three independent preparations. KCa3.1, Kir2.1, and CD11b were expressed exclusively in microglia, while
Nav1.8 and CAMK2-a expressions were characteristic of neurons and GFAP expression characteristic of astrocytes. n = 3/group; one-way ANOVA
follow by Bonferroni post hoc test. (B–D) Hippocampal slices were treated with 100 nmol/L AbO for 24 h. (B) Slices were immunostained with
CD11b (green) or anti-GFAP (green) and co-stained with anti-KCa3.1 (APC064). AbO treatment caused increased staining of KCa3.1, which was
largely colocalized with CD11b, but not with the astrocytic marker GFAP. AbO-induced KCa3.1 upregulation was further corroborated by the
increased transcript (qPCR result in C, n = 4) and protein (representative Western blot and quantification in D, n = 4) levels of KCa3.1. Numerical
data are presented by mean  SE from four independent experiments and were analyzed by two-sample t-test.
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Figure 2. Microglial KCa3.1 expression is elevated in brains of 4- and 10-month-old 5xFAD mice. (A) Corresponding coronal sections of mouse
frontal cortex from 10-month-old mice were fluorescently stained with the amyloid dye anti-CD11b (green), anti-KCa3.1 (either APC064 or
P4997) (red), and FSB (blue). KCa3.1 was localized to activated microglia enriched around FSB-positive amyloid plaques. (B) Higher magnification
images to illustration localization of KCa3.1 to compartments different from but contiguous to or overlapping with CD11b (white arrowheads) in
a 5xFAD brain. Quantitative PCR (C) and Western blotting (D) showed increased cerebral transcript and protein levels, respectively, of KCa3.1 in
5xFAD mice. In (D), the left panel shows a representative Western blot using 10-month-old mouse samples, and the right panel shows quantified
mean intensities of the KCa3.1 band relative to that of 1-month-old Wt mice. Numerical data are presented by mean  SE and were analyzed by
two-sample t-test or two-way ANOVA follow by Bonferroni post hoc test. qPCR (10 mo): Wt, n = 9 and 5xFAD, n = 12; Western blotting: (1 mo)
Wt, n = 5 and 5xFAD, n = 5; (4 mo) Wt, n = 5 and 5xFAD, n = 5; (10 mo) Wt, n = 8 and 5xFAD, n = 9.
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receptor-dependent hLTP. Notably, minocycline (a tetra-
cycline inhibitor of microglial activation) and iNOS
reduction were found to prevent the hLTP disruption by
Ab,30 suggesting that microglial activation and microglial
NO production contribute to the detrimental effect of Ab
on synaptic function. Because KCa3.1 inhibition blocks
AbO-induced microglial neurotoxicity as well as NO pro-
duction in hippocampal slices,9 we hypothesized that
KCa3.1 blockade is able to prevent the microglia-related
deleterious effect of AbO on hLTP. Indeed, in the hLTP
induced in Schaffer-collateral-CA1 synapses following
high frequency stimulation, application of AbO to mouse
hippocampal slices blocked hLTP induction at 20–
100 nmol/L.16 Co-perfusion of TRAM-34 recovered hLTP
from AbO-induced reduction (Fig. 5A and B).
To determine if such an effect can be demonstrated
in vivo, we used 5xFAD mice, for whom AbO-related
hLTP deficits have been demonstrated.31 We intraperi-
toneally injected TRAM-34 (40 mg/kg) or vehicle into 12-
month-old 5xFAD mice and age-matched Wt littermates,
sacrificed them at 24-hours post-injection, and obtained
hippocampal slices for recording. The magnitude of hLTP
induction was significantly reduced in 5xFAD mice
compared to Wt littermates, but was significantly
increased to the Wt level in TRAM-34-treated 5xFAD
mice (Fig. 5C and D). Taken together, our data suggest
that KCa3.1 blockade ameliorates neuroinflammation and
associated synaptic impairments induced by AbO.
Senicapoc is an orally available, brain
penetrant KCa3.1 blocker
Although TRAM-34 readily passes the blood brain barrier
(Cbrain/Cplasma = 1.2)
32 and is widely used as a tool com-
pound for proof-of-concept rodent studies, it is not opti-
mal for clinical use due to its lack of oral availability and
short half-life.33 To identify a clinically promising KCa3.1
inhibitor, we investigated the pharmacokinetic properties
and the brain penetration of two other published KCa3.1
blockers: a phenyl-pyran, reported by chemists at Bayer,34
and senicapoc35 (Fig. 6A). The Bayer 4-phenyl-4H-pyra
exhibited good brain penetration (Cbrain/Cplasma~3) but
had a short half-life of 15 min following intravenous
administration at 10 mg/kg in mice (data not shown).
We next resynthesized senicapoc (Fig. 6A), an orally
available KCa3.1 blocker structurally similar to TRAM-
34.12 The purity of our senicapoc preparations was 96.9%
(see Data S1). Despite its long (~7 day) half-life in
humans,12 senicapoc exhibited a relatively short but phar-
macologically acceptable half-life of roughly 1 h in mice
and 4 h in rats (data not shown). Its brain concentrations
on average were 5–7 times higher than plasma concentra-
tions in both mice and rats (Fig. 6B). At one hour after
intraperitoneal injection at 50 mg/kg, brain concentra-
tions averaged 43  8 lmol/L (n = 3) in mice and
43  7 lmol/L (n = 2) in rats. A more detailed time
CA B
300
200
100
0
-100
TRAM-34
Control
0 +40-40-80
pA 5xFAD
(mV)
300
200
100
0
-100
Control
0 +40-40-80
pA Wt
(mV)
Figure 3. Enhanced KCa3.1 channel membrane expression in 5xFAD microglia. Whole-cell patch-clamp was performed on microglia acutely
isolated from 10-month-old 5xFAD or Wt littermate mice. (A) Representative current elicited by a voltage ramp from -120 mV to +40 mV
showing a Ca2+-activated current in Wt microglia in the presence of 1 lmol/L free Ca2+ in the internal recording solution. (B) Increased
Ca2+-activated K+ current recorded from 5xFAD microglia was blocked by the specific KCa3.1 blocker TRAM-34. (C) Scatter plots showing a
statistically greater KCa3.1 channel current density for 5xFAD microglia (n = 20) compared to Wt microglia (n = 20). Shown are mean  S.E.
Statistical difference was determined by Student’s t-test (P = 0.02), following a natural log transform of the outcome which met the
assumption of normality.
Table 2. Summary of human brain samples.
Cases Alzheimer’s disease Cognitively normal controls
Number 13 9
Mean Age ( SE) 81.1 ( 2.2) 83.4 ( 3.0)
% Male 43.5% 57.1%
Braak Stage V-VI I-II
# with Stroke 1.0 (7.6%) 0
ª 2019 University of California. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of
American Neurological Association. 729
L.-W. Jin et al. KCa3.1 Inhibitors for Alzheimer’s Disease
BC D
A
Figure 4. Increased KCa3.1 expression in Alzheimer’s disease brains. KCa3.1 expression was assessed in 13 Alzheimer’s disease (AD) and nine age-
and sex-matched control brain samples from the superior temporal cortex. (A) Sections were fluorescently stained with FSB (blue) and anti-KCa3.1
(PA5:41015, red). KCa3.1 immunoreactivity is substantially increased in AD brains, and is enriched in or around amyloid plaques. (B) Co-staining
with anti-KCa3.1 (left panel: AV35098, right panel: P4997), anti-Iba-1, and FSB using AD sections again shows enhanced KCa3.1 immunoreactivity
in or around amyloid plaques. Many Iba-1 + cells show KCa3.1 immunoreactivity (arrows). KCa3.1 immunoreactivity does not co-localized with
FSB-positive fibrillary amyloid. (C–D) Western blot of superior temporal cortex homogenates showed increased cerebral levels of KCa3.1 in AD
brains. Statistical analysis was conducted using nonparametric Wilcoxon rank sum test instead of t-test due to non-normality of the data.
730 ª 2019 University of California. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of
American Neurological Association.
KCa3.1 Inhibitors for Alzheimer’s Disease L.-W. Jin et al.
course in mice revealed that senicapoc brain concentra-
tions were significantly higher than plasma concentrations
for at least 6 h after intraperitoneal administration
(Fig. 6C). Senicapoc further achieved good plasma con-
centrations following oral gavage administration (Fig. 6D)
with an oral availability of roughly 60%.
A B
C D
Figure 5. KCa3.1 inhibition mitigates AbO-induced impairment in hLTP. (A–B) TRAM-34 co-perfusion prevented the inhibitory effect of AbO on
amplitude of hLTP induced with high-frequency stimulation (HFS). Hippocampal slices were incubated with TRAM-34 (1 lmol/L) for 45 min and
with AbO (50 nmol/L) for 10 min before recording, and perfused continuously with both throughout the recording. (A) Representative traces show
the fEPSP of baseline (black trace) and at 60 min (red trace) after HFS. (B) Summary bar graphs showing the average fEPSP slope between 50 and
60 min after HFS. Data were compiled from recordings using slices obtained from the groups of control (five slices from five mice), AbO (eight slices
from six mice), and AbO+TRAM-34 (eight slices from six mice). AbO alone significantly inhibited the level of hLTP and this effect was prevented by
co-application of TRAM-34. All data are presented as mean  SE. One-way ANOVA follow by Bonferroni post hoc test. *P < 0.005. (C–D)
Intraperitoneally injected TRAM-34 prevented the inhibitory effect of AbO on amplitude of hLTP induced with HFS. Twelve-month-old 5xFAD and
Wt littermates received intraperitoneal TRAM-34 (40 mg/kg) or vehicle only and the brain removed 24 h post-injection for hLTP analysis. (C)
Representative traces and time course of hLTP induced with HFS. (D) Summary bar graphs showing the average fEPSP slope between 50 and
60 min, compiled from recordings of Wt/vehicle (10 slices from three mice), Wt/TRAM-34 (10 slices from three mice), 5xFAD/vehicle (10 slices from
three mice), and 5xFAD/RAM-34 (10 slices from three mice). 5xFAD mice had reduced amplitudes of hLTP but this reduction was mitigated by
TRAM-34 injection. All data are presented as mean  SE. Two-way ANOVA follow by Bonferroni post hoc test. *P < 0.05 and **P < 0.001.
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Senicapoc rectifies Ab-related microglial
activation and neurotoxicity
Despite senicapoc’s structural similarity to TRAM-34 and
its demonstrated selectivity for KCa3.1,35,36 its effect on
microglial activation has not been studied. We next deter-
mined if senicapoc rectifies AbO-induced microglial
abnormalities. In primary microglial cultures, senicapoc
was able to block AbO-induced microglial KCa3.1 cur-
rents (Fig. 7A), microglial proliferation (Fig. 7B), expres-
sion of microglial activation mediators IL-1b, IL-6 and
iNOS (Fig. 7C), activation of p38MAPK (Fig. 7D), and
production of NO (Fig. 7E). These in vitro effects are
identical to those reported for TRAM-34.9
We subsequently tested the in vivo effects of seni-
capoc by feeding six-month-old 5xFAD mice with a
senicapoc-medicated diet. To determine if this medi-
cated diet was able to achieve pharmacologically relevant
senicapoc concentrations, we measured the morning (9
am) plasma and brain levels in two weeks after starting
the diet. The result showed that brain senicapoc levels
ranged between 1 and 2.5 lmol/L (Fig. S3). Considering
senicapoc’s IC50 of 11 nmol/L for KCa3.1 inhibition and
its protein binding of 95%, such brain concentrations
are sufficient to exert a pharmacodynamic effect.35,36
Following ad lib access to the medicated diet for three
months, senicapoc curbed microglial activation as evi-
denced by reduced CD11b immunoreactivity (45%
reduction, P < 0.001, Fig. 8A). Similar reductions in
Iba-1 and CD68 immunoreactivities were also observed
(Fig. S4). Senicapoc treatment also significantly reduced
the number of microglia expressing KCa3.1 (Fig. 8B).
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Figure 6. The KCa3.1 inhibitor senicapoc is orally available and has excellent brain penetration. (A) Chemical structures of the three indicated
KCa3.1 blockers and the synthetic scheme for senicapoc. (B) Total plasma and brain concentrations in mice (n = 3) and rats (n = 2) at 1 h after
intraperitoneal administration of 50 mg/kg senicapoc in 1 mL miglyol per body weight. (C) Time course of total senicapoc brain and plasma
concentrations in mice after intraperitoneal administration of 50 mg/kg senicapoc (n = 3 per time point). (D) Total senicapoc plasma
concentrations after oral gavage of 50 mg/kg in rats (n = 3). Data are presented as mean  SD.
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qPCR showed significantly reduced expressions of proin-
flammatory modulators IL-1b, TNF-a, IL-6, and iNOS
(Fig. 8C), but no changes in several markers typical of
an M2-like phenotype (Fig. S5). Interestingly, it also
resulted in a 39% reduction (P < 0.001) of cerebral
amyloid deposits (Fig. 8A). Levels of TBS-soluble and
TBS-insoluble/SDS-soluble Ab142 were reduced 22%
and 35%, respectively, when measured by ELISA (Fig.
8D). This observation was corroborated with Western
blotting for Ab following Tricine gel electrophoresis
(Fig. 8E).
As reductions of soluble Ab species and microglial acti-
vation following senicapoc treatment may help mitigate
synaptic impairment, we further tested if KCa3.1 inhibi-
tion by senicapoc in vivo would improve hLTP.31 Indeed,
we found that senicapoc treatment rectified the reduced
induction of hLTP in 5xFAD mice to the level of Wt mice
(Fig. 8F and G).
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Figure 7. Senicapoc reduces proinflammatory microglial activation in vitro. Cultured primary microglia were activated by AbO for 24 h in the
presence of senicapoc or vehicle control. Consistent with our previous observations,9 AbO (100 nmol/L) induced in microglia (A) a large KCa3.1
current as shown by whole-cell patch clamp; (B) microglial proliferation; (C) increased transcript levels of proinflammatory modulators as shown
by qPCR; (D) time-dependent increases in the level of phosphor-p38MAPK as shown by Western blotting; and (E) increased NO production. All
these proinflammatory changes were significantly reduced by senicapoc (1 lmol/L if not otherwise indicated).
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Discussion
Therapies aimed at microglia face several challenges as
activated microglia can exert both beneficial and harmful
effects in AD. Such therapies should ideally: (1) achieve
reduced neurotoxicity while maintaining or enhancing
neuroprotective functions of microglia, such as phagocy-
tosis of Ab aggregates; (2) be relatively specific to micro-
glia to avoid adversely affecting important neuronal
functions; (3) not be broadly immunosuppressive. We
consider inhibition of KCa3.1 would selectively modulate
microglial activation by “fine-tuning” Ca2+ signaling and
selectively modulating activation signaling pathways. Evi-
dence from our laboratory and others’ indicates that
KCa3.1 blockers inhibit microglia-mediated neurotoxicity
without affecting microglial migration and phagocytosis.4–
10 Moreover, KCa3.1 blockers are very mild immunosup-
pressants that do not affect the ability of rodents to clear
infections.10 Therefore in this study, we intended to use
animal models and human postmortem brain samples to
show that KCa3.1 is a biologically relevant and microglial
target for AD. Several conclusions can be drawn: (1) sol-
uble AbO, the highly toxic Ab species implicated as one
of the principal initiators of AD phenotypes, enhances
microglial KCa3.1 activity; (2) KCa3.1 is required for
AbO-induced microglial proinflammatory activation and
neurotoxicity; (3) KCa3.1 expression/activity is upregu-
lated in transgenic AD animals and human AD brains;
and (4) pharmacological inhibition of KCa3.1 with
TRAM-34 or senicapoc in mice mitigates some key AD-
like phenotypes including neuroinflammation, hLTP defi-
cit and amyloid pathology. Our study supports that
KCa3.1 is a candidate therapeutic target for AD.
KCa3.1 appears particularly upregulated in amyloid
plaque-associated microglia, notably in human AD brains
(Fig. 4). Recent evidence suggests that plaque-associated
microglia and plaque-distant microglia are in different
activation states,37 with plaque-associated microglia
exhibiting a “hyperactive” state.38 Plescher et al. found
that, in acute cerebral slices of the TgCRND8 mouse
model of AD, plaque-associated microglia expressed sig-
nificant Kv and Kir currents with the latter most likely
attributed to Kir2.1..37 This result is consistent with our
previous finding of enhanced microglial Kv and Kir2.1
activity/expression in 5xFAD mice,16 but the role of
KCa3.1 was not investigated. It would be interesting in
future experiments using single-cell approaches to deter-
mine the KCa3.1 expression and activity in plaque-asso-
ciated microglia or in “disease-associated microglia
(DAM)”, a unique microglia-type recently identified in
5xFAD mice that has the potential to restrict neurodegen-
eration,39 and to test if inhibition of KCa3.1 in such
subgroups of microglia affects their disease-related
phenotype.
The significance of microglia in modulating AD-like
amyloid pathology remains controversial. Our in vivo
data (Fig. 8A–E) of substantial reductions of soluble and
insoluble Ab species in mice chronically treated with
senicapoc suggest that KCa3.1 inhibition may enhance
the microglial Ab clearance capacity that is suppressed
in AD transgenic mice.40,41 Our result is consistent with
several reports showing that modulation of specific
microglial signaling pathways alters Ab deposition and
clearance,40,42–47 but appears contradictory to reports
showing that inducible microglia depletion by genetic or
pharmacological means fails to affect amyloid pathology
in transgenic AD models.48,49 Although further studies
are needed to resolve this controversy, our data using
K+ channel expression as a readout show that the micro-
glial activation profiles in transgenic AD mice are com-
plex.16 Therefore, differences in the timing and
approaches of neuro-immunomodulation to alter micro-
glia quantity or signaling may differentially influence the
outcomes.
One limitation of our study is that we could not
demonstrate significant memory deficits in 5xFAD/control
diet mice compared to Wt mice at 9 months of age
despite their large cerebral amyloid load, therefore the
Figure 8. The effect of chronic oral senicapoc treatment in 5xFAD mice. Six-month-old 5xFAD and Wt littermates were fed ad lib senicapoc-
medicated or control diet (n = 9 per group) for three months and the brains removed for analysis. (A) Frontal cortex sections co-stained with anti-
CD11b and FSB showed that senicapoc diet reduced the CD11b and FSB reactivities in 5xFAD brains. (B) Frontal cortex sections co-stained with
anti-CD11b and anti-KCa3.1 (APC064) were analyzed by co-localization analysis. 5xFAD mice showed increased % of microglia expressing KCa3.1,
which was reduced by senicapoc treatment. (C) The transcript levels of indicated proinflammatory modulators in acutely isolated microglia were
increased in 5xFAD mice consuming control diet, compared to the Wt littermates. Senicapoc diet reduced the expression of all four modulators.
Two-way ANOVA follow by Bonferroni post hoc test. (D) The fresh brains were fractionated into TBS-soluble and TBS-insoluble, SDS-soluble
fractions, which were used for ELISA quantification of Ab42. Senicapoc diet significantly reduced the levels of Ab42 in both fractions. Two-way
ANOVA follow by Bonferroni post hoc test. (E) The ELISA result was corroborated with Tricine gel electrophoresis/Western blotting, which showed
reduced Ab band (arrow) intensities in both TBS-solule and SDS-soluble fractions of 5xFAD brains. (F) Traces and time course of hLTP induced with
HFS. (G) Summary bar graphs showing the average fEPSP slope between 50 and 60 min, compiled from recordings of Wt/control (eight slices from
five mice), Wt/Senicapoc (eight slices from five mice), 5xFAD/control (12 slices from six mice), and 5xFAD/senicapoc (10 slices from six mice). Data
are expressed as mean percent change in fEPSP slope  SE. from baseline. Two-way ANOVA follow by Bonferroni post hoc test. *P < 0.005,
**P < 0.001. 5xFAD mice on control diet had reduced amplitudes of hLTP but this reduction was mitigated by senicapoc diet.
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cognitive benefit of senicapoc could not be demonstrated
in our current trial. Two tasks were tested: novel object
recognition and step-through passive avoidance. Using
these two tests, we did successfully demonstrated deficits
in 10-month-old APP/PS1 [B6.Cg-Tg(APPswe,PSEN1dE9)
85Dbo/Mmjax] mice in our prior study,16 arguing against
technical issues. Future therapeutic trials using alternative
models and larger numbers of animals are warranted.
Based on our data, here we propose repurposing seni-
capoc for AD treatment. Drug repurposing offers a rapid
and economic route to the clinic than new drug discov-
ery, which on average takes at least 15 years and $1.5
billion to bring a new successful drug to the market. It
is therefore advantageous to reposition known targets,
such as KCa3.1, for which a wealth of pharmacological
knowledge has been accumulated, and safety has been
demonstrated. Our finding that senicapoc is brain pene-
trant (Cbrain/Cplasma~5) and orally available makes it suit-
able for the potential treatment of AD. Senicapoc was
initially developed for sickle cell anemia. Since K+ efflux
through KCa3.1 is a major pathway for erythrocyte
dehydration during sickling,50 it appeared very promising
to test KCa3.1 inhibitors, which had been shown to pre-
vent erythrocyte dehydration in both patients51 and
mouse models.52 The Phase-2 clinical trial showed that
senicapoc reduced hemolysis and increased hemoglobin
levels.12 However, in Phase-3, senicapoc failed to achieve
its primary clinical end-point, which was reduction in
the rate of vaso-occlusive pain crisis, despite clearly
improving all hematological parameters.53 Since seni-
capoc were demonstrated safe and well-tolerated in
humans, it was deposited in the NIH National Center
for Advancing Translational Research (NCAT) library as
PF-05416266, making it available for investigator-
initiated clinical trials. In conclusion, our preclinical data
support that repurposing of senicapoc has the potential
to expedite the urgently needed new drug discovery for
AD.
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